Lauren Massaro

A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.

Study results outlined in a poster at ASHP Midyear 2023 revealed that virtual delivery education programs could contribute to a more inclusive and accessible health care information landscape for Black older adults.

A poster from ASHP Midyear 2023 demonstrated the effectiveness of liposomal bupivacaine as it is used for cesarean section procedures, regarded as an area with increasing utilization.

In a conversation from this year's Healthcare Advocate Summit, Randy Falkenrath demystified the oncology medication management model and explained how specialty pharmacist can help patients access care.

Maintaining the structure and function of antibody biologics like faricimab is critical for their administration via intravitreal injection (IVI), a common treatment approach for retinal diseases.

Study findings offer critical insight into the development of sex-specific treatment and prevention strategies for Alzheimer’s disease.

Increased health care access to devices like the continuous glucose monitor (CGM) could improve health outcomes for underserved patients who may otherwise be hindered from their use.

Findings detailing long-term breast cancer outcomes for women who received a false-positive result underscore the significance of false-positive results as a critical public health issue.

The FDA approval marks an important public health milestone in the ongoing effort to empower patients to take control of their own health.

The initiative will address the dire need to improve the lack of research on women’s health, one that has led to unfavorable health outcomes for the population.

Presenters at a NCPA 2023 session highlighted the importance of overcoming hesitations to implement new clinical services and taking an employee-centric approach in doing so.

Understanding critical risk factors associated with the use of electronic nicotine delivery systems (ENDS) may help mitigate the harm dealt to youths by such devices.

The combination vaccine produced robust immune responses from vaccine candidates in a phase 1/2 clinical trial.

Newly approved by the FDA, Celltrion’s infliximab-dyyb (Zymfentra) offers patients with inflammatory bowel disease a more innovative administrative approach to infliximab treatment.